DY-131


Catalog No. size PriceQuantity
M6405-2 2mg solid $94
M6405-10 10mg solid $360

Description

DY131, also known as GSK-9089, is a novel selective agonist at estrogen-related receptors ERRβ and ERRγ. DY131 could potentiate the ERRgamma-induced growth inhibition in LNCaP-ERRgamma and DU145-ERRgamma cells in a dose-dependent manner. ERRgamma may perform an antiproliferative or tumor-suppressing function in prostate cancer cells. ERRgamma could be a novel therapeutic target for prostate cancer treatment.

Product information

CAS Number: 95167-41-2

Molecular Weight: 311.38

Formula: C18H21N3O2

Synonym:

GSK 9089

DY-131

DY 131

GSK9089

GSK-9089

Chemical Name: N'-[(1E)-[4-(diethylamino)phenyl]methylidene]-4-hydroxybenzohydrazide

Smiles: CCN(CC)C1C=CC(/C=N/NC(=O)C2C=CC(O)=CC=2)=CC=1

InChiKey: WLKOCYWYAWBGKY-CPNJWEJPSA-N

InChi: InChI=1S/C18H21N3O2/c1-3-21(4-2)16-9-5-14(6-10-16)13-19-20-18(23)15-7-11-17(22)12-8-15/h5-13,22H,3-4H2,1-2H3,(H,20,23)/b19-13+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Solubility (25°C) DMSO: 62 mg/mL(199.11 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

DY131 is an ERRβ/γ-specific ligand that displays preferential selectivity for ERRγ at lower concentrations. It has no activity on the related receptors ERRα, ERα and ERβ. DY131 inhibits growth in a diverse panel of breast cancer cell lines, causing cell death that involves the p38 stress kinase pathway and a bimodal cell cycle arrest. ERRβ2 facilitates the block in G2/M, and DY131 delays progression from prophase to anaphase. ERRβ2 is a cytosolic protein that also localizes to centrosomes, and DY131 treatment leads to the appearance of multi- and monopolar spindles, thus causes mitotic spindle defects.

References:

  1. Heckler MM, et al. Oncotarget. 2016, 7(30):47201-47220.
  2. Yu DD, et al. Bioorg Med Chem Lett. 2005, 15(5):1311-3.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed